Red blood cells (RBCs) are biocompatible carriers that can be employed to deliver different
bioactive substances. In the past few decades, many strategies have been developed to …

Nano drug-delivery systems (DDS) may significantly improve efficiency and reduce toxicity
of loaded drugs, but a few nano-DDS are highly successful in clinical use. Unprotected …

Red blood cells (RBCs), or erythrocytes, have been promising endogenous candidates for
drug delivery for more than four decades. Armed with a better understanding of the diverse …

Background There is currently much interest in cancer cell targeting and tumor penetrating
for research and therapeutic purposes. Purpose To improve targeting delivery of antitumor …

Thrombus formed in blood vessel is a progressive process, which would lead to life-
threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the …

Eukaryotic cells are defined as cells containing distinct nuclei and other membranous
organelles. However, red blood cells (RBCs) lack a nucleus and organelles—perhaps to …

The development of drug-loading technology will bring new and rapid development to the
treatment of diseases. At present, drug delivery by nanoparticles, erythrocyte, and platelet …

Digestive system cancer is the most common cause of cancer death in the world. Although
cancer treatment options are increasingly diversified, the mortality rate of malignant cancer …

Scientific organizations worldwide are striving to create drug delivery systems that provide a
high local concentration of a drug in pathological tissue without side effects on healthy …

Red blood cells (RBCs) are the most abundant cell type in the blood, and play a critical role
in oxygen transport. With the development of nanobiotechnology and synthetic biology …